NanoViricides Reports Positive Anti-viral Effect of HIV Drug
NanoViricides' anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.
View ArticleNew York Biotechnology Association Gears Up for its 21st Annual Meeting
New York Biotechnology Association (NYBA) will develop its Emerging Companies Showcase at the NYBA 21st Annual Meeting, May 2 in New York City at the Marriott Marquis Hotel.
View ArticleNanoViricides Announces Issuance of a Fundamental Patent in the USA
NanoViricides, Inc. (OTC BB: NNVC) announced that a fundamental patent, on which the nanoviricides® technology is based, is due to be issued in the USA on May 8, 2012. The issuance notification was...
View ArticleOneMedRadio: NanoViricides CEO Discusses U.S. Patent
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
View ArticleThe Technology Corner: 3 Companies That Could Eradicate Ebola Virus
To the scientific community, the Ebola virus is one of the most noxious pathogens identified to date. To the general population, the virus is dreadful, made especially frightening in pop culture.
View ArticleNanoViricides: Big Things In a Small Package
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.
View ArticleNanoViricides’ drug FluCide found safe in small animal studies
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug...
View Article